Atgam Disease Interactions
There are 2 disease interactions with Atgam (lymphocyte immune globulin, anti-thy (equine)).
Lymphocyte immune globulin, anti-thy (equine) (applies to Atgam) immunocompromised
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency, Vaccination
Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine). Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient. There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists. If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.
Lymphocyte immune globulin, anti-thy (equine) (applies to Atgam) renal/liver
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease
The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine). It is recommended to evaluate these tests closely in these patients.
Switch to professional interaction data
Atgam drug interactions
There are 174 drug interactions with Atgam (lymphocyte immune globulin, anti-thy (equine)).
Report options
More about Atgam (lymphocyte immune globulin, anti-thy (equine))
- Atgam consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- Drug class: selective immunosuppressants
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Promacta
Promacta is used to prevent bleeding episodes in patients with chronic immune (idiopathic) ...
Alvaiz
Alvaiz (eltrombopag) is an oral thrombopoietin receptor agonist that may be used to treat certain ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Leukine
Leukine increases white blood cells and decreases the risk of infection in conditions such as ...
Sargramostim
Sargramostim is used for aplastic anemia, bone marrow transplantation, bone marrow transplantation ...
Eltrombopag
Eltrombopag is used for aplastic anemia, immune thrombocytopenia, thrombocytopenia ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.